Opendata, web and dolomites

DEALS

Biomarker assay development to expedite ALS experimental therapeutic advancement

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DEALS project word cloud

Explore the words cloud of the DEALS project. It provides you a very rough idea of what is the project "DEALS" about.

therapies    founded    gained    14    progressive    developer    detectable    monitoring    final    successful    orphan    diseases    medicinal    sclerosis    25    therapy    swallowing    market    rare    slowing    als    spasticity    instrumental    eradicate    difficulties    economic    dutch    respiratory    designation    revenues    time    breathing    mission    drug    sme    die    earth    quick    disease    delay    tests    accurate    soon    mainly    earlier    tool    muscle    received    excluding    initial    clinical    2012    wasting    diagnosed    symptom    diagnosis    mostly    deals    speed    speeding    walking    amyotrophic    lack    interventions    entrepreneurs    weakness    therapeutic    biomarkers    practical    severely    patients    diagnostic    lateral    combination    efficacy    onset    feasibility    assays    paper    additional    speaking    progression    benefit    symptoms    perform    moving    trials    ema    characterised    treeway    assay    stem    proof    million    foreseen   

Project "DEALS" data sheet

The following table provides information about the project.

Coordinator
TREEWAY B.V. 

Organization address
address: SEVILLAWEG 142
city: ROTTERDAM
postcode: 3047AL
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.treeway.nl/treeway-receive-h2020-grant-for-biomarker-feasibility-study
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TREEWAY B.V. NL (ROTTERDAM) coordinator 50˙000.00

Map

 Project objective

The unique Dutch SME Treeway B.V. was founded in 2012 by two highly experienced and successful entrepreneurs that both have been diagnosed with amyotrophic lateral sclerosis (ALS). It is Treeway’s mission to eradicate ALS from the face of the earth by speeding up ALS research and bringing new therapies in the market as soon as possible. Treeway already has one new therapy in clinical development, which has recently received EMA’s Orphan Medicinal Product Designation.

ALS is a rare disease that is characterised by muscle spasticity and rapidly progressive weakness due to muscle wasting. This results in difficulties in walking, moving, speaking, swallowing, and breathing. Most ALS patients die from respiratory failure within three years. ALS diagnosis currently is mainly aimed at excluding other diseases with similar symptoms. As a result there is a 9–14-month delay between symptom onset and final diagnosis of ALS. For similar reasons, there is also a lack of accurate and practical diagnostic tests for monitoring the benefit of potential therapeutic interventions for ALS. This is severely slowing down the progression of clinical drug development in this field.

As ALS drug developer, Treeway will greatly benefit from the availability of a (combination of) quick diagnostic assay(s) to be used in monitoring therapeutic efficacy in clinical trials. In addition, the ALS diagnostic tool may also proof to be instrumental for (speeding up) the initial diagnosis of the disease.

Therefore, within DEALS, Treeway will perform a mostly paper study to investigate the technical and economic feasibility of developing a quick and reliable diagnostic tool. These developments will be based on known and detectable biomarkers of the disease. Economic benefit will stem from the ability of the assays to enable earlier diagnosis and to speed up clinical drug development; per one month gained in development time for a new ALS drug, about €25 million additional revenues can be foreseen.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DEALS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DEALS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

PD_Pal (2019)

Palliative care in Parkinson’s disease

Read More